IMRN vs VXRT vs NVAX vs IBRX vs MRK

For growth investors, ImmunityBio, Inc.

(IBRX) is the stronger pick with 22. 7% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Novavax, Inc. (NVAX) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate Vaxart, Inc. (VXRT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 4. 0x versus Merck & Co. , Inc. at 15. 3x.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +69. 5%, compared to -93. 7% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: MRK returned +164. 7% versus VXRT's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 45β versus Novavax, Inc. 's 2. 22β — meaning NVAX is approximately 389% more volatile than MRK relative to the S&P 500. On balance sheet safety, Immuron Limited (IMRN) carries a lower debt/equity ratio of 1% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ImmunityBio, Inc.

(IBRX) is pulling ahead at 22. 7% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to 8. 0% for Merck & Co. , Inc.. Over a 3-year CAGR, VXRT leads at 1204% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -28. 0% for ImmunityBio, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -23. 3% for IBRX. At the gross margin level — before operating expenses — VXRT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VXRT: 189.

6% to $2. 00.

In this comparison, MRK (2.

9% yield) pays a dividend. IMRN, VXRT, NVAX, IBRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +164. 7%, NVAX: -89. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMRN is a small-cap high-growth stock; VXRT is a small-cap high-growth stock; NVAX is a small-cap high-growth stock; IBRX is a small-cap high-growth stock; MRK is a large-cap deep-value stock. MRK pays a dividend while IMRN, VXRT, NVAX, IBRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.